Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis

Transplant Infectious Disease

Volumn 17, Issue 2, 2015, Pages 242-249

  Crocchiolo, R ^a   Bramanti, S ^a   Vai, A ^a   Sarina, B ^a   Mineri, R ^a   Casari, E ^a   Tordato, F ^a   Mauro, E ^a   Timofeeva, I ^a   Lugli, E ^a   Mavilio, D ^a,b   Carlo Stella, C ^a,b   Santoro, A ^a   Castagna, L ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antimicrobial prophylaxis; Cyclophosphamide; Haploidentical stem cell transplantation; Hematologic malignancies; Infections; T cell replete

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; BUSULFAN; CASPOFUNGIN; CIDOFOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECHINOCANDIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; LEVOFLOXACIN; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; RITUXIMAB; TACROLIMUS; THIOTEPA; VORICONAZOLE; IMMUNOSUPPRESSIVE AGENT;

ACUTE HEPATITIS; ADULT; AGED; APLASIA; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; INFECTION PREVENTION; INFECTION RATE; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; SYSTEMIC MYCOSIS; T CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS REACTIVATION; WHOLE BODY RADIATION; BACTERIAL INFECTIONS; CYSTITIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; POLYOMAVIRUS INFECTIONS; PROCEDURES; VIRUS DISEASES; YOUNG ADULT;

ADULT; AGED; BACTERIAL INFECTIONS; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYSTITIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; POLYOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIRUS DISEASES; YOUNG ADULT;

EID: 84925344665     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12365     Document Type: Article

References (20)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med 2010; 363: 2091-2101.
2. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230-2239.
3. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
4. Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602-606.
5. Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adult with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86-94.
6. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
7. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Mulanovich VE, Jiang Y, de Lima M, Shpall EJ, Champlin RE, Ciurea SO. Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res 2011; 1: 98-105.
11. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007; 13: 1304-1312.
12. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1835-1844.
13. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117-122.
14. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859-1866.
15. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant 2013; 13: 179-188.
16. Kanakry JA, Kasamon YL, Bolaños-Meade J, et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013; 19: 1514-1517.
17. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
18. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
19. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010; 17: 493-499.
20. Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood 2011; 117: 6768-6776.